Here are five points:
1. An increase in funding to advance orthobiologics will spur market growth.
2. Many vendors are investing in research for new product development.
3. Strategic marketing partnerships will also drive market growth.
4. Spinal fusion costliness will hinder orthobiologics’ sales.
5. Key market players include DePuy Synthes, Medtronic, Sanofi, Stryker and Zimmer Biomet.
More articles on devices:
Providence Medical Technology DTRAX system boasts positive results for cervical radiculopathy treatment: 5 takeaways
Medtronic, NuVasive lead US MIS interbody fusion market: 7 observations
Atlas Spinal Care to offer new cervical radiculopathy treatment: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
